Related Experiment Videos
Interferon treatment of cirrhotic patients with chronic hepatitis C
R Idilman1, N De Maria, A Colantoni
1Transplantation Center, University of Kentucky, Lexington, USA.
Insights
Hepatitis C virus (HCV) infection affects millions, with interferon (IFN) showing promise. This review examines IFN treatment effectiveness in patients with HCV cirrhosis, comparing their response rates to those with chronic active HCV.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Hepatitis C virus (HCV) infection is a significant global health concern, affecting millions and leading to severe liver complications.
- Despite advances in screening, effective treatment for chronic HCV, particularly in cirrhotic patients, remains a challenge.
- Hepatocellular carcinoma and decompensated cirrhosis are common outcomes for individuals with chronic HCV.
Purpose of the Study:
- To review existing data on interferon (IFN) treatment for HCV-positive individuals with cirrhosis.
- To compare the treatment response rates of cirrhotic patients to those with chronic active HCV.
- To evaluate the efficacy and safety of IFN therapy in managing chronic Hepatitis C virus infection.
Main Methods:
- Review of available clinical data and studies on interferon therapy for HCV.
- Comparative analysis of treatment outcomes in HCV patients with cirrhosis versus chronic active hepatitis.
- Assessment of remission rates and viral clearance in treated patient cohorts.
Main Results:
- Interferon (IFN) therapy has demonstrated the ability to induce remission of hepatic inflammation and achieve viral clearance in some HCV cases.
- The effectiveness of IFN therapy in cirrhotic patients is still under investigation, with ongoing debate regarding patient selection, dosage, and duration.
- Preliminary data suggests a need for further research into IFN's role in managing HCV-related liver disease progression.
Conclusions:
- A safe and effective treatment strategy for chronic HCV, especially in the presence of cirrhosis, is still needed.
- Interferon remains a key therapeutic option, but its application in cirrhotic patients requires careful consideration and further research.
- Understanding the comparative response rates is crucial for optimizing treatment protocols for diverse HCV patient populations.
Abstract:
Hepatitis C virus (HCV) infection is one of the more important infectious diseases yet to be conquered. An estimated 3.5 million people in the USA have chronic HCV. Each year, 8000 to 10000 of these chronically infected patients die of a liver-related complication of their infection. The introduction of effective blood screening assays has resulted in a remarkable decrease in the incidence of post-transfusion HCV infection. Nonetheless it is essential to have a treatment programme for chronic HCV disease that prevents the development and the progression of compensated cirrhosis to either decompensated cirrhosis or hepatocellular carcinoma, as many individuals present to the health care system with chronic active hepatitis or cirrhosis. A completely safe and effective treatment strategy for chronic HCV, with or without cirrhosis, remains to be developed. Of the various treatment alternatives currently available, only interferon (IFN) has been evaluated extensively. IFN therapy has been shown to induce remissions of the hepatic inflammatory process and also to eliminate the viral infection in some treated cases. As a result, the selection of patients for treatment and the dose and the duration of therapy with IFN are still controversial issues. It is widely held that cirrhotic individuals do not respond to IFN therapy and that treatment of decompensated cirrhotic individuals with HCV infection is dangerous. Here we review data regarding the available experience with IFN treatment of HCV-positive individuals with cirrhosis and compare the response rates of cirrhotics to those reported for individuals with chronic active HCV.